Parallel Bio Secures $21 Million in Series A to Advance Human-First Drug Discovery
Signs on Eight Pharmaceutical Partners and Completes First Preclinical Study from Immune Organoid Platform with Centivax
CAMBRIDGE, Mass., June 12, 2025--(BUSINESS WIRE)--Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round attracted prominent leaders in AI and biotech, including new investors Amplo and Marc Benioff, founder and CEO of Salesforce, and existing investors Metaplanet, Humba Ventures, Atypical Ventures, Undeterred Capital, and Jeff Dean.
The company also revealed that 8 pharmaceutical partners, including three Fortune 500 companies, are testing more than 50 drugs and immunotherapies using its organoid-based immune system platform—including Centivax, which completed the first preclinical testing on the platform for its universal flu vaccine candidate.
"With these milestones, we are closer to making human-first drug discovery the new industry standard," said Robert DiFazio, CEO and co-founder at Parallel Bio. "For too long, the reliance on lab mice to model human biology has come at a high cost: 95% of drugs fail in human trials even after succeeding in animal studies. We're turning that on its head by using organoids and AI to discover drugs in true-to-life human models from the start."
Parallel Bio will use the new capital to scale the AI and automation capabilities of its organoid-based immune system platform, expand its team of scientists and engineers, and support growing pharmaceutical partnerships. To date, Parallel Bio has raised a total of nearly $30 million, including this Series A and previous seed rounds.
Parallel Bio's platform combines lymph-node organoids with AI and robotics to replicate the human immune system at scale across diverse populations. Organoids are 3D, self-assembling models of human biology. These miniature organs mimic an organ's structure and function and the body's response to disease or treatment, as if the organoids were individual patients.
AIX Ventures partner Krish Ramadurai, who joined the company's board of directors as part of the round, commented: "Parallel Bio is redefining drug development by turning the conventional model upside down—transforming today's 95% failure rate into a pathway for 95% success. Their groundbreaking human-first platform unlocks biological insights previously impossible to capture, accelerating the development of effective treatments that reach patients faster while generating de novo biological data to power the next generation of AI-driven therapeutics. We're thrilled to partner with the Parallel Bio team in setting a new gold standard for the future of medicine."
Since launching Clinical Trial in a Dish last year, Parallel Bio has seen growing demand from pharmaceutical companies. This first commercial application accurately predicts the safest and most effective drug candidates for human trials.
"Starting with human models enables new drugs to reach the market at a pace never possible before," said Juliana Hilliard, Parallel Bio co-founder and chief scientific officer. "We aim to slash $2 billion and 9 years from each drug candidate in development by predicting success at the earliest stages of discovery."
Centivax Validates Broad Immune Response in Organoid Trial
Parallel Bio partnered with Centivax, a universal immunity biotechnology company, to generate human-first data to validate Centivax's first program: a universal flu vaccine called Centi-Flu that is now in manufacturing for human clinical trials, with the first patient expected to be dosed early next year.
"Parallel Bio enables us to derisk the single biggest source of failure in vaccine development: making sure the vaccines work in humans before the human trials have even begun," said Jacob Glanville, president and CEO at Centivax. "Even though we have validated our pan-influenza responses in mice, rats, pigs, and ferrets, ultimately we are making a universal vaccine for humans. Parallel Bio's platform is transformative by allowing us to directly validate our results in immune organoids derived from adult humans."
The organoid study revealed the power of the Centi-Flu technology: by effectively targeting common features of the virus shared by many different influenza strains, Centi-Flu even produces strong immune responses against strains not included in the vaccine. Human immune organoids were "vaccinated" with Centi-Flu, leading to the production of B cells capable of reacting to a wide variety of flu strains. The immune organoids were derived from patients with prior flu exposure, proving that Centi-Flu could trigger broad humoral responses in flu-exposed individuals.
The organoid model also showed activation of CD4+ and CD8+ T cells, which are important for fighting infections, suggesting that Centi-Flu helps stimulate both antibody production and T cell immunity. This combination is particularly valuable for protecting against severe flu, including hospitalization and death.
About Parallel Bio
Parallel Bio is pioneering human-first drug discovery by combining organoids and AI to create true-to-life models of human biology. The company developed the first platform that replicates the human immune system across diverse populations, predicting drug success and identifying disease targets with accuracy and speed far beyond the limits of traditional animal models. Pharmaceutical partners, including three Fortune 500 companies, are using its Clinical Trial in a Dish to test the safety and efficacy of immunotherapies. Based in Cambridge, Mass., Parallel Bio was founded in 2021 by two scientists behind the world's first scalable human immune organoid.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612697548/en/
Contacts
Media contactMatt Hickspress@parallel.bio
Business contactRobert DiFaziobd@parallel.bio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Best's Market Segment Report: 2024 Pricing Cuts in U.S. Cyber Generated First-Ever Reduction in Direct Premiums Written
OLDWICK, N.J., June 23, 2025--(BUSINESS WIRE)--Premiums generated from cyber insurance coverage declined by 2.3% to slightly less than $7.1 billion in 2024 compared with a year earlier, marking the first ever decrease in the segment since the data was first collected in 2015, according to a new AM Best report. Despite the drop in premium, the loss ratio for the U.S. cyber segment remained below the 50% mark in 2024, suggesting that the line of coverage is still profitable for those who choose to underwrite the risk. According to the report, the decrease in premiums is driven more by pricing changes than any changes in exposure. "When premium grew during the hard market cycle, the growth significantly outpaced the pricing increases, indicating that demand for cyber insurance was increasing as well," said Christopher Graham, senior industry analyst, AM Best. "Considering that the premium decrease is close to the pricing decrease, that would indicate that the demand for cyber insurance is steady." However, the report also notes that some large organizations may be shifting their cyber exposure to their own single-parent captive insurers. Such organizations that have a favorable loss experience find it beneficial to maintain the premium under the parent company's structure and typically don't file the related cyber data reports with the National Association of Insurance Commissioners. Among the report's other highlights: Much of the new capacity during the hard market came from surplus lines writers. Those carriers have held—and marginally increased—their market share even as the total premium slightly contracted; Surplus lines paper remains the prime spot for complicated cyber risks, and this is evident through the split among primary, excess, and endorsement coverage. While surplus lines writers benefited from the hard market pricing of 2020-2022, that benefit seems to have now worn off. When new writers enter the market during a hard market cycle, those writers get the benefit of the stronger pricing without having to pay the legacy losses. AM Best has maintained a stable outlook on the global cyber insurance segment, citing a cautious level of underwriting in a dynamic risk environment. To access the full copy of the Best's Market Segment Report on U.S. cyber insurance, please visit AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED. View source version on Contacts Christopher Graham Senior Industry Analyst +1 908 882 1807 Fred Eslami Associate Director +1 908 882 1759 Christopher Sharkey Associate Director, Public Relations +1 908 882 2310 Al Slavin Senior Public Relations Specialist +1 908 882 2318
Business Wire
35 minutes ago
- Business Wire
Best's Market Segment Report: 2024 Pricing Cuts in U.S. Cyber Generated First-Ever Reduction in Direct Premiums Written
BUSINESS WIRE)--Premiums generated from cyber insurance coverage declined by 2.3% to slightly less than $7.1 billion in 2024 compared with a year earlier, marking the first ever decrease in the segment since the data was first collected in 2015, according to a new AM Best report. Despite the drop in premium, the loss ratio for the U.S. cyber segment remained below the 50% mark in 2024, suggesting that the line of coverage is still profitable for those who choose to underwrite the risk. According to the report, the decrease in premiums is driven more by pricing changes than any changes in exposure. 'When premium grew during the hard market cycle, the growth significantly outpaced the pricing increases, indicating that demand for cyber insurance was increasing as well,' said Christopher Graham, senior industry analyst, AM Best. 'Considering that the premium decrease is close to the pricing decrease, that would indicate that the demand for cyber insurance is steady.' However, the report also notes that some large organizations may be shifting their cyber exposure to their own single-parent captive insurers. Such organizations that have a favorable loss experience find it beneficial to maintain the premium under the parent company's structure and typically don't file the related cyber data reports with the National Association of Insurance Commissioners. Among the report's other highlights: Much of the new capacity during the hard market came from surplus lines writers. Those carriers have held—and marginally increased—their market share even as the total premium slightly contracted; Surplus lines paper remains the prime spot for complicated cyber risks, and this is evident through the split among primary, excess, and endorsement coverage. While surplus lines writers benefited from the hard market pricing of 2020-2022, that benefit seems to have now worn off. When new writers enter the market during a hard market cycle, those writers get the benefit of the stronger pricing without having to pay the legacy losses. AM Best has maintained a stable outlook on the global cyber insurance segment, citing a cautious level of underwriting in a dynamic risk environment. To access the full copy of the Best's Market Segment Report on U.S. cyber insurance, please visit
Business Wire
an hour ago
- Business Wire
The Hackett Group ®: Research Shows Gen AI Helps Top HR Teams Drive Engagement, Efficiency and Strategic Impact
MIAMI--(BUSINESS WIRE)-- The Hackett Group, Inc. (NASDAQ: HCKT), a leading generative artificial intelligence (Gen AI) consultancy and executive advisory firm, today released its 2025 Digital World Class ® Human Resources (HR) research. It reveals how top-performing HR organizations are redefining excellence. Digital World Class® HR organizations – those achieving top-quartile performance in both business value and operational excellence – are achieving 29% lower cost while supporting three times more employees. The report shows that Digital World Class ® HR organizations – those achieving top-quartile performance in both business value and operational excellence – are achieving 29% lower cost while supporting three times more employees. This reflects a strategic approach to scaling impact, not doing more with less. These HR leaders are embracing Gen AI and advanced automation to expand the capacity of HR teams, unlock time for higher-value work, and reshape the function into a more agile, insight-driven partner to the business. This trend is about building a better workforce experience to more effectively enable business objectives. 'Digital World Class ® HR organizations aren't just managing talent – they're unlocking the full potential of their people with digital capabilities,' said Jessica Haley, principal and Global Human Resources Executive Advisory practice leader at The Hackett Group ®. 'These organizations are showing what's possible when you combine human insight with digital enablement and AI. They are not reducing the function; they are elevating the impact of HR. Amplifying the power of HR to drive stronger business outcomes at scale, fostering resilience, and leading the way in shaping the workplace and the workforce – that is Digital World Class ® HR and that is the future.' Key findings: What sets Digital World Class ® HR apart The Hackett Group's research, which draws from global benchmark studies across hundreds of companies, highlights distinguishing characteristics of top-performing HR organizations: 1. They are more integrated with business strategy and engaged with business stakeholders. 2X more time working directly with line leaders on business-aligned talent plans 2.4X more likely to be seen as a valued partner by business stakeholders 57% more roles filled internally, signaling stronger alignment between talent development and business needs 2. They prioritize enterprise-level initiatives like strategic workforce planning. 32% more staff focused on strategic workforce planning 40% more organizational development efforts built into success metrics Stronger emphasis on change enablement, with more HR staff dedicated to facilitating business transformation 3. They invest more in AI, automation and digital enablement of HR service delivery. 2.3X more likely to offer self-service automation for HR data, compliance and reporting 2X more likely to align human capital management application strategies to enterprise goals 71% of primary software functionality is actively used, maximizing technology return on investment and scalability Digital World Class ® HR organizations are also significantly more agile in navigating disruption, enabling faster adaptation to shifting workforce dynamics, economic headwinds and regulatory demands. Closing the performance gap: A blueprint for transformation The research outlines a clear road map on leveraging Gen AI to reshape the HR service delivery model and close the Digital World Class ® performance gap: Address long-term workforce talent needs proactively by leveraging emerging tools to optimize workforce planning, skill development and internal mobility. Employ intelligent automation for routine HR work and transactional processes to open capacity for HR to focus on more strategic work. Identify and address your HR team's skills gaps; embrace new ways of working, such as co-intelligence; and elevate HR's strategic impact by strengthening data savviness and storytelling. Drive operational efficiency by collaborating with AI-focused partners who emphasize ethical AI practices, transparency and trust. Evolve the HR operating model into an integrated, aligned, digitally enabled model that empowers HR teams to drive strategic value for the business. A public version of the research paper, ' Driving HR Performance With Gen AI ' is available for free with registration. About The Hackett Group ® The Hackett Group, Inc. (NASDAQ: HCKT) is an IP and platform-based, Gen AI strategic consulting and executive advisory firm that enables Digital World Class ® performance. Using AI XPLR™ and ZBrain™ – our ideation through implementation platforms – our experienced professionals help organizations realize the power of Gen AI and achieve quantifiable, breakthrough results, allowing us to be key architects of their Gen AI journey. Our expertise is grounded in unparalleled best practices insights from benchmarking the world's leading businesses – including 97% of the Dow Jones Industrials, 90% of the Fortune 100, 70% of the DAX 40 and 51% of the FTSE 100. Visit us at Trademarks The Hackett Group ®, quadrant logo, and Digital World Class ® are the registered marks of The Hackett Group ®. Cautionary Statement Regarding 'Forward-Looking' Statements This release contains 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements including without limitation, words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' or other similar phrases or variations of such words or similar expressions indicating, present or future anticipated or expected occurrences or outcomes are intended to identify such forward-looking statements. Forward-looking statements are not statements of historical fact and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. Factors that may impact such forward-looking statements include without limitation, the ability of The Hackett Group ® to effectively market its digital transformation, our ability to transition our capabilities to support generative artificial intelligence (AI)-related consulting services and solutions and other consulting services, our ability to effectively integrate acquisitions, including the Spend Matters acquisition into our operations, our ability to manage joint ventures and successfully cooperate with our joint venture partners, competition from other consulting and technology companies that may have or develop in the future, similar offerings, the commercial viability of The Hackett Group ® and its services as well as other risk detailed in The Hackett Group's reports filed with the United States Securities and Exchange Commission. The Hackett Group ® does not undertake any duty to update this release or any forward-looking statements contained herein.
